Science 37 Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Science 37 Holdings Inc (SNCE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Science 37 Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 60M vs 25,635M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.2% annualized vs trailing 12 months), vs decelerating (-43.1%) for its tracked peer group.
- Growth: Science 37 Holdings Inc generated -8.4% revenue growth year over year in Q3 2023, vs -31.3% for its tracked competitors combined.
- Profitability: Its 0.0% net margin compares with 11.2% for the peer group.
- Peer revenue share: Science 37 Holdings Inc accounted for 0.4% of combined revenue among its tracked peer group, up from 0.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.11M compares with $0.22M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SNCE Sales vs. its Competitors, Q3 2023
Science 37 Holdings Inc reported revenue contraction of 8.38 % year on year in Q3 2023, above its competitors' combined revenue change of -31.27 %.
With a net margin of -0.01 %, Science 37 Holdings Inc reported lower profitability than its competitors (11.15 %).
Science 37 Holdings Inc generated 0.41 % of the combined sales of its peer group, up from 0.31 % a year earlier.
Science 37 Holdings Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Science 37 Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Science 37 Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Science 37 Holdings Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs -8.4% for Science 37 Holdings Inc. Science 37 Holdings Inc's share of combined industry revenue moved from 0.03% to 0.03%, a gain of 0.00 percentage points.
Science 37 Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Science 37 Holdings Inc | - | - | - | Yes |
| Competitors combined (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SNCE Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Medpace Holdings Inc | 282.9% | Outperformed |
| 2 | Labcorp Holdings Inc | 282.9% | Outperformed |
| 3 | Icon Plc | 282.9% | Outperformed |
| 4 | Clarus Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Science 37 Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Science 37 Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Science 37 Holdings Inc | 679.34 | 60.26 |
| Labcorp Holdings Inc | 25,287.16 | 14,348.00 |
| Medpace Holdings Inc | 17,656.37 | 2,782.29 |
| Icon Plc | 13,180.90 | 8,251.34 |
| Syneos Health Inc | 4,484.71 | 5,418.97 |
| Clarus Corporation | 131.22 | 253.42 |
| SUBTOTAL | 61,419.70 | 31,114.28 |
Sources: Science 37 Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Science 37 Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Science 37 Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Labcorp Holdings Inc | Diagnostics 78.08 % |
| Medpace Holdings Inc | Reportable 100.00 % |
| Syneos Health Inc | Clinical Solutions 74.80 % |
| Clarus Corporation | Outdoor Segment 72.65 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Science 37 Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Science 37 Holdings Inc | 679 | 109,565 | -201,325 |
| Labcorp Holdings Inc | 25,287 | 204,971 | 14,336 |
| Medpace Holdings Inc | 17,656 | 448,756 | 79,274 |
| Icon Plc | 13,181 | 205,769 | 5,719 |
| Syneos Health Inc | 4,485 | 216,759 | 2,849 |
| Clarus Corporation | 131 | 649,797 | -80,664 |
| PEERS TOTAL | 60,740 | 219,169 | 12,450 |
Science 37 Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Icon Plc | Ireland 38.58 % |
| Syneos Health Inc | North America 59.90 % |
| Clarus Corporation | Geographic Distribution Foreign 60.00 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Science 37 Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (58 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.2x | 37.0x | -36.8x |
| EV / EBITDA | -1.0x | 18.0x | -18.9x |
| P/B | 0.0x | 2.9x | -2.9x |
| Return on Equity | 88.15 % | industry aggregate | 88.87 % |
| Return on Invested Capital | -39.29 % | -4.04 % (avg) | -35.25 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Science 37 Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 88.9 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-43.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Science 37 Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Science 37 Holdings Inc | 4.03 | 5.04 | - |
| Labcorp Holdings Inc | 0.22 | 1.61 | 0.66 |
| Medpace Holdings Inc | 0.36 | 0.72 | - |
| Icon Plc | 0.20 | 1.10 | 0.43 |
| Syneos Health Inc | - | 1.15 | 0.77 |
| Clarus Corporation | 0.81 | 4.43 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Science 37 Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Science 37 Holdings Inc | Q3 2023 | -8.4 % | - |
| Labcorp Holdings Inc | Q2 2026 | +5.8 % | +25.5 % |
| Medpace Holdings Inc | Q2 2026 | +17.2 % | +34.5 % |
| Icon Plc | Q4 2025 | -0.4 % | -69.0 % |
| Syneos Health Inc | Q2 2023 | +0.4 % | -99.0 % |
| Clarus Corporation | Q2 2026 | +2.7 % | - |
| PEERS TOTAL | +2.0 % | -41.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Science 37 Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Science 37 Holdings Inc | Q3 2023 | -26.2 % | -5.6 % |
| Labcorp Holdings Inc | Q2 2026 | +5.6 % | +68.9 % |
| Medpace Holdings Inc | Q2 2026 | +19.5 % | +291.2 % |
| Icon Plc | Q4 2025 | +4.4 % | +3.7 % |
| Syneos Health Inc | Q2 2023 | +3.5 % | -26.5 % |
| Clarus Corporation | Q2 2026 | -18.0 % | -40.7 % |
Science 37 Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Science 37 Holdings Inc | - | - | - |
| Labcorp Holdings Inc | 5.40% | 6.11% | 11.58% |
| Medpace Holdings Inc | 24.84% | 35.54% | 110.15% |
| Icon Plc | 1.41% | 1.68% | 2.49% |
| Syneos Health Inc | 0.87% | 1.09% | 2.06% |
| Clarus Corporation | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Science 37 Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Science 37 Holdings Inc | - | 11.27 |
| Labcorp Holdings Inc | 25.53 | 1.76 |
| Medpace Holdings Inc | 36.44 | 6.35 |
| Icon Plc | 57.47 | 1.60 |
| Syneos Health Inc | 62.33 | 0.83 |
| Clarus Corporation | 8.77 | 0.52 |
| PEERS AVERAGE | 37.15 | 1.97 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.